Journal
EMBO JOURNAL
Volume 34, Issue 12, Pages 1609-1611Publisher
WILEY-BLACKWELL
DOI: 10.15252/embj.201591697
Keywords
-
Categories
Funding
- MRC [MC_U105178808] Funding Source: UKRI
- Medical Research Council [MC_U105178808] Funding Source: researchfish
- Medical Research Council [MC_U105178808] Funding Source: Medline
Ask authors/readers for more resources
REV7/MAD2L2 plays important roles in translesion DNA synthesis and mitotic control. Two new papers extend its gamut by revealing its unexpected participation in pathway choice during DNA double-strand break repair. By inhibiting 5' DNA end resection downstream of 53BP1 and RIF1, REV7/MAD2L2 promotes non-homologous end joining at the expense of homologous recombination. Importantly, loss of REV7/MAD2L2 renders PARP inhibitors ineffective in BRCA1-deficient tumours, suggesting another possible mechanism for the acquisition of resistance to this important new class of drug.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available